Dermatitis News and Research

Latest Dermatitis News and Research

Pruritic nodules and aluminium allergy arise after vaccinations or treatments for allergies

Allergic contact dermatitis from aluminium has previously been considered very unusual. However, there are now reports of pruritic nodules and aluminium allergy arising after vaccinations or treatments for allergies.

14 Dec 2010

Diet linked to onset of mental illness

Changes in diet have been linked to a reduction of abnormal behaviors in mentally ill people or animals, but a Purdue University study shows that diet might also trigger the onset of mental illness in the first place.

14 Dec 2010

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today the presentation of new preclinical data for CYC065, a novel, orally-available, cell cycle kinase inhibitor. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

6 Dec 2010

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Cyclacel Pharmaceuticals, Inc. announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes refractory to hypomethylating agents, such as azacitidine and decitabine. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

6 Dec 2010

Mothers exposure to farm animals and cats during pregnancy lowers risk of atopic dermatitis in children

Children whose mothers are exposed to farm animals and cats are better protected against atopic dermatitis and are less likely to develop this painful inflammation of the skin in their first two years of life. A group of researchers from the University of Zurich and other universities have published evidence supporting this theory in the Journal of Allergy & Clinical Immunology.

3 Dec 2010

RegeneRx receives patent for Tβ4 to prevent immunological responses from toxic agents

RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.

2 Dec 2010

Black rice may help soothe inflammation: Research

The latest episode in the American Chemical Society's (ACS) award-winning podcast series, "Global Challenges/Chemistry Solutions," focuses on the discovery that black rice a little-known variety of the grain that is the staple food for one-third of the world's population may help soothe the inflammation involved in allergies, asthma and other diseases.

1 Dec 2010

Anacor, UCSF and NYBC collaborate to discover drug therapies for river blindness

Anacor Pharmaceuticals, the University of California San Francisco (UCSF) Sandler Center and the Lindsley F. Kimball Research Institute (LFKRI) of the New York Blood Center (NYBC) today announced the establishment of a research and development collaboration to discover new drug therapies for the treatment of river blindness (onchocerciasis), a parasitic disease that is the second leading cause of infectious blindness worldwide, and is most prevalent in Africa.

1 Dec 2010

Anacor completes initial public offering of common stock

Anacor Pharmaceuticals, Inc. today announced the completion of its initial public offering of 12,000,000 shares of its common stock at a price of $5.00 per share.

30 Nov 2010

Anacor prices initial public offering of common stock

Anacor Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price of $5.00 per share.

24 Nov 2010

Provectus reports progress in PV-10 program for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company's Phase 2 trial of PV-10 for metastatic melanoma, as well as more than 30 new patients.

24 Nov 2010

Arthritis Foundation, Covidien join forces to help Americans suffering from osteoarthritis

The Arthritis Foundation and Covidien have joined forces to help advance awareness and support for millions of people suffering from osteoarthritis in the United States.

23 Nov 2010

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Cyclacel Pharmaceuticals, Inc. announced today that updated Phase 2 clinical trial results of sapacitabine for the treatment of myelodysplastic syndromes (MDS) will be presented at a poster presentation during the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, on Saturday, December 4, 2010.

19 Nov 2010

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

The 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) brings together leading allergists and immunologists from around the world.

12 Nov 2010

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.

11 Nov 2010

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).

10 Nov 2010

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has held its second meeting with the Australian Therapeutic Goods Administration ("TGA") to discuss milestones for approval of PV-10 for treatment of metastatic melanoma. The TGA is the part of the Australian Government's Department of Health and Ageing responsible for the assessment, approval and monitoring of therapeutic goods available in Australia. The initial meeting with the TGA was held in October 2008.

9 Nov 2010

bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction

bitop AG, a biotech company specializing in the development of Ectoin®-containing medical devices, announced the inclusion of the first patient into a clinical trial on the Ectoin inhalation solution in patients with inflammation and airway obstruction.

8 Nov 2010

Amgen wins Scrip Best New Drug award for Prolia

Amgen is pleased to announce that it has won the Best New Drug award for Prolia™ (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the 2010 Scrip Awards ceremony Nov. 4 in London. Named one of TIME's Top 10 Medical Breakthroughs of 2009, Prolia is the first treatment specifically designed to target osteoclasts, the cells that break down bone.

8 Nov 2010

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented positive preliminary data from fully monitored study data for the entire study population of 80 subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma.

8 Nov 2010

Dermatitis News and Research

Latest Dermatitis News and Research

Pruritic nodules and aluminium allergy arise after vaccinations or treatments for allergies

Diet linked to onset of mental illness

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Mothers exposure to farm animals and cats during pregnancy lowers risk of atopic dermatitis in children

RegeneRx receives patent for Tβ4 to prevent immunological responses from toxic agents

Black rice may help soothe inflammation: Research

Anacor, UCSF and NYBC collaborate to discover drug therapies for river blindness

Anacor completes initial public offering of common stock

Anacor prices initial public offering of common stock

Provectus reports progress in PV-10 program for metastatic melanoma

Arthritis Foundation, Covidien join forces to help Americans suffering from osteoarthritis

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction

Amgen wins Scrip Best New Drug award for Prolia

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Dermatitis News and Research

Latest Dermatitis News and Research

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in